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ABSTRACT 
 
Host plasma membrane protein SERINC5 is incorporated into budding retrovirus particles where 
it blocks subsequent entry into susceptible target cells. Three accessory proteins encoded by 
diverse retroviruses, HIV-1 Nef, EIAV S2, and MLV Glycogag, each independently disrupt 
SERINC5 antiviral activity, by redirecting SERINC5 from the site of virion assembly on the 
plasma membrane to an internal RAB7+ endosomal compartment. Pseudotyping retroviruses 
with particular glycoproteins, e.g., the vesicular stomatitis glycoprotein (VSV G), renders the 
infectivity of particles resistant to inhibition by virion-associated SERINC5. To better understand 
viral determinants for SERINC5-sensitivity, the effect of SERINC5 was assessed using HIV-1, 
MLV, and M-PMV virion cores, pseudotyped with glycoproteins from Arenavirus, Coronavirus, 
Filovirus, Rhabdovirus, Paramyxovirus, and Orthomyxovirus genera. Infectivity of particles, 
pseudotyped with HIV-1, amphotropic-MLV, or influenza virus glycoproteins, was decreased by 
SERINC5, whether the core was provided by HIV-1, MLV, or M-PMV. Particles generated by 
all three cores, and pseudotyped with glycoproteins from either avian leukosis virus-A, human 
endogenous retrovirus K (HERV-K), ecotropic-MLV, HTLV-1, Measles morbillivirus, 
lymphocytic choriomeningitis mammarenavirus (LCMV), Marburg virus, Ebola virus, severe 
acute respiratory syndrome-related coronavirus (SARS-CoV), or VSV, were insensitive to 
SERINC5. In contrast, particles pseudotyped with M-PMV, RD114, or rabies virus (RABV) 
glycoproteins were sensitive to SERINC5, but only with particular retroviral cores. Resistance to 
SERINC5 by particular glycoproteins did not correlate with reduced SERINC5 incorporation 
into particles or with the route of viral entry. These findings indicate that some non-retroviruses 
may be sensitive to SERINC5 and that, in addition to the viral glycoprotein, the retroviral core 
influences sensitivity to SERINC5. 
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IMPORTANCE 
 
The importance of SERINC5 for inhibition of retroviruses is underscored by convergent 
evolution among three non-monophyletic retroviruses, each of which encodes a structurally 
unrelated SERINC5 inhibitor. One of these retroviruses causes tumors in mice, a second anemia 
in horses, and a third causes AIDS. SERINC5 is incorporated into retrovirus particles where it 
blocks entry into target cells, via a mechanism that is dependent on the viral glycoprotein. Here 
we demonstrate that retroviruses pseudotyped with glycoproteins from several non-retroviruses 
are also inhibited by SERINC5, suggesting that enveloped viruses other than retroviruses may 
also be inhibited by SERINC5. Additionally, we found that sensitivity to SERINC5 is 
determined by the retrovirus core, as well as by the glycoprotein. By better understanding how 
SERINC5 inhibits viruses we hope to extend fundamental understanding of virus replication and 
of the native role of SERINC5 in cells, and perhaps to advance the development of new antiviral 
strategies.  
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INTRODUCTION 
 
HIV-1 Nef is important for maximal HIV-1 replication in vivo and for progression to 
AIDS (1–3). Nef is a multifunctional accessory protein that downregulates CD4, MHC, and TCR 
from the cell surface (4–8). Nef also enhances HIV-1 infectivity in single-round infection 
experiments (9–16) by overcoming the antiviral effects of SERINC5 and SERINC3 (17, 18), 
though, of the two, SERINC5 is the more potent restriction factor. SERINC5 is incorporated into 
budding virions where it inhibits subsequent fusion of the virion membrane with target cell 
membranes. Nef counteracts SERINC5 by removing it from the cell surface so that it is not 
incorporated into nascent virions (17–20). 
HIV-1 is not the only virus inhibited by SERINC5. SIVs lacking nef are also inhibited by 
SERINC5 and SIV nefs counteract this inhibition (17) with a potency that is  proportional to the 
prevalence of SIV in wild primate populations (21). Two examples of convergent evolution of 
anti-SERINC function by virally encoded proteins are found outside of primate 
immunodeficiency viruses. Murine leukemia virus (MLV) Glycogag and equine infectious 
anemia virus (EIAV) S2 are viral antagonists of SERINC5 activity, and neither share sequence 
or structural homology with Nef, nor to each other (17, 22–24). 
The mechanism by which virion-associated SERINC5 inhibits HIV-1 entry is unknown. 
The block is manifest after virion attachment to target cells, apparently at the stage of fusion pore 
expansion; virion contents mix with target cell cytoplasm but virion core transfer to the 
cytoplasm is inhibited (17, 19). Otherwise isogenic virions pseudotyped with HIV-1 Env 
glycoproteins from different HIV-1 isolates exhibit a range of dependency on Nef and of 
sensitivity to SERINC5 (25, 26). SERINC5 increases HIV-1 sensitivity to antibodies and 
peptides targeting the membrane-proximal external region of gp41, suggesting that it somehow 
alters the conformation of the HIV-1 glycoprotein near the virion membrane (19, 25). 
Importantly, HIV-1 particles pseudotyped with vesicular stomatitis virus (VSV) G or Ebola virus 
glycoprotein are resistant to SERINC5 antiviral activity (17, 18, 24). These initial observations 
suggest a correlation between the location of viral fusion and sensitivity to SERINC5 activity, 
with glycoproteins that mediate fusion at the cell surface (Env from HIV-1 and amphotropic 
MLV [A-MLV]) being sensitive and those that mediate fusion in endo-lysosomal compartments 
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(VSV-G and Ebola GP) being resistant (17, 24). Taken together these results indicate that the 
virion glycoprotein is a viral determinant of sensitivity to SERINC5. 
SERINC5 is a multipass transmembrane that localizes almost exclusively to the plasma 
membrane  (17, 18).  As such, in the absence of counter-measures, all enveloped viruses would 
be expected to encounter SERINC5 during viral egress, and to potentially be subject to its 
antiviral effects. We sought to address the breadth of SERINC5 antiviral activity and assess 
whether the route of entry impacts the sensitivity of viral glycoproteins to the antiviral effects of 
SERINC5. To do so, we investigated whether the co-expression of SERINC5 during viral 
production could inhibit a variety of glycoprotein pseudotypes of HIV, MLV, or M-PMV cores. 
Using this system, we tested the sensitivity of a number of retroviral Envs as well as 
representative glycoproteins from the Arenavirus, Coronavirus, Filovirus, Rhabdovirus, 
Paramyxovirus, and Orthomyxovirus genera. Consistent with previous findings, we observed 
that glycoprotein is a major determinant of SERINC5 sensitivity. While many glycoproteins 
were universally insensitive to the antiviral effects of SERINC5, the glycoproteins from NL4.3, 
A-MLV, and influenza were inhibited by SERINC5 in all viral core pseudotypes tested. No 
correlation was observed between SERINC5 sensitivity and the route of viral entry mediated by 
the viral glycoprotein. Unexpectedly, we also observed that sensitivity to SERINC5 antiviral 
activity for M-PMV, RD114, and rabies virus (RABV) glycoproteins depended on the retroviral 
core onto which they were pseudotyped. Our findings reveal that an interplay between virion 
core and glycoprotein determines the sensitivity to SERINC5 antiviral activity. 
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RESULTS 
 
To determine which viral glycoproteins are sensitive to the antiviral activity of SERINC5 
we assessed infectivity of pseudotyped GFP-expressing lentiviral vectors produced in the 
presence or absence of SERINC5. Included in this panel was a diverse selection of retroviral Env 
glycoproteins, including those from human immunodeficiency virus-1 (HIV-1), avian leukosis 
virus A (ALV-A), human endogenous retrovirus K (HERV-K), feline endogenous retrovirus 
RD114, Mason-Pfizer monkey virus (M-PMV), ecotropic MLV (EcoMLV), amphotropic murine 
leukemia virus (A-MLV), and human T-cell lymphoma virus-1 (HTLV-1). We also tested the 
glycoproteins from an assortment of RNA viruses including influenza (H7/N1), parainfluenza 5 
(PIV5), measles, rabies virus (RABV), lymphocytic choriomeningitis virus (LCMV), Marburg 
virus (MARV), Ebola virus Zaire [Mayinga] (EBOV), severe acute respiratory virus coronavirus 
(SARS CoV), and vesicular stomatitis virus (VSV). For these experiments we considered 
glycoprotein pseudotypes to be sensitive to SERINC5 restriction if viral titer was reduced at least 
10-fold in the presence of SERINC5. 
Similar to the findings of others (17, 18, 24), we observed that SERINC5 causes a greater 
than 100-fold reduction in viral infectivity for HIV-1 and A-MLV pseudotypes, while no 
significant reduction was observed for EBOV and VSV pseudotypes (Fig. 1A and Table 1). 
Interestingly, we observed >10-fold reduction of infectivity of H7/N1 influenza and RABV 
pseudotypes. No other pseudotypes displayed >10-fold reduced infectivity with SERINC5. 
These observations indicate that restriction by SERINC5 is not dictated by how the viral 
glycoprotein mediates fusion, as fusion mediated by influenza (27) or by RABV (28) occurs in a 
pH-dependent fashion in the endo-lysosomal compartment, while HIV-1- (29, 30), A-MLV-, M-
PMV- and HTLV-1-mediated (31) fusion occurs in a pH-independent manner.  
Next we tested a panel of filoviral glycoproteins for sensitivity to SERINC5 restriction. 
All of these glycoproteins require proteolytic processing (32, 33) following internalization into 
the target cell and utilize the lysosomal protein NPC1 to initiate viral fusion (34, 35).  In addition 
to the EBOV and MARV glycoproteins tested in Fig 1A, this panel included glycoproteins from 
Bundibugyo (BDBV), Lloviu (LLOV), Reston (RESTV), Sudan (SUDV), Taï Forest (TAFV), 
and the 2014 Makona glycoprotein variant (A82) that initiated the 2013-2016  outbreak , along 
with an infectivity-enhancing derivative (GP-A82V) that arose during the outbreak (36, 37). As 
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shown in Fig. 1B, none of the filoviral glycoproteins were inhibited >10-fold in the presence of 
SERINC5. However, there may be modest differences in sensitivity to SERINC5 activity, 
specifically  RESTV and TAFV GP appear slightly more sensitive (4.3- and 2.9-fold, 
respectively) to SERINC5 inhibition compared to either Mayinga or Makona Ebola virus 
glycoproteins (1.65- and 1.2-fold, respectively). 
HIV-1 Nef, MLV glygoGag, and EIAV S2 counteract SERINC5 antiviral activity by 
removing SERINC5 protein from the cell surface and relocalizing it to an endosomal 
compartment (17, 18, 22). The ability of a viral glycoprotein to re-localize a normally plasma 
membrane localized antiviral protein has been previously shown for HIV-2 Env and human 
BST2 (38). Thus, we reasoned that viral glycoproteins may confer resistance to SERINC5 
activity by re-localizing SERINC5 to an internal membrane compartment. To test this, we 
compared SERINC5 incorporation into HIV-1 virus-like particles (VLPs) pseudotyped with the 
various glycoproteins shown in Fig 1A. We found that HIV-1 VLPs universally incorporated 
SERINC5 irrespective of the viral glycoprotein present (Figure 2). In replicate blotting, only 
HERV-K Env showed a consistently lower level of SERINC5 incorporation into viral particles 
(data not shown). However, this observation is likely to be caused by pleiotropic effects of cells 
transfected with this glycoprotein, as cell growth was significantly reduced compared to other 
transfections, and reduced levels of Gag and GFP were also observed (Fig. 2, data not shown). 
Regardless, no direct correlation between SERINC5 exclusion from virions and resistance to its 
antiviral effects was evident. 
A previous report indicated that MLV virions pseudotyped with RD114 Env are 
susceptible to the antiviral effects of SERINC5 (24). However, in the presence of SERINC5 we 
only observed a modest ~4.5-fold reduction in viral titer of RD114 pseudotyped HIV-1 virions 
(Fig. 1A). In response to this discrepancy, we sought to determine if the viral core modulates 
susceptibility to SERINC5 antiviral activity. Thus, we tested the same panel of glycoproteins for 
SERINC5 sensitivity when pseudotyped on different virion cores. First, we tested the SERINC5 
sensitivity of the same panel of glycoproteins as in Fig. 1A on MLV viral cores (Figure 3A and 
Table 1). We observed that the glycoproteins sensitive to SERINC5 restriction on HIV-1 cores 
(HIV-1, A-MLV, Flu, and Rabies) were also restricted when pseudotyped on MLV cores. 
Additionally, we observed that M-PMV Env was sensitive to SERINC restriction when 
pseudotyped onto MLV cores, whereas it was not when pseudotyped onto HIV-1 cores. 
.CC-BY-NC-ND 4.0 International licensenot certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (which wasthis version posted September 24, 2019. . https://doi.org/10.1101/780577doi: bioRxiv preprint 
 8
Returning to the initial impetus for exploring different cores, we observed a ~7.5-fold reduction 
of infectivity for RD114 pseudotyped MLV cores when produced in the presence of SERINC5, 
which is similar to the magnitude of the inhibitory effect reported by Ahi et al. (24). 
Due to observed differences in SERINC5 sensitivity with M-PMV pseudotypes of HIV-1 
and MLV cores, we next tested for SERINC5 antiviral activity against our panel of glycoproteins 
pseudotyped onto M-PMV cores (Figure 3B and Table 1). These experiments showed that the 
infectivity of M-PMV cores bearing M-PMV Env was significantly reduced in the presence of  
SERINC5. Furthermore, we observed that pseudotypes of M-PMV cores with HIV-1, A-MLV, 
and Flu glycoproteins were sensitive to SERINC5 restriction, similar to the observations with 
both HIV-1 and MLV cores. In contrast to observations with HIV-1 and MLV cores, the 
SERINC5-mediated reduction of infectivity for M-PMV cores pseudotyped with RD114 (~20-
fold) surpassed our 10-fold cutoff for significance. Conversely, rabies virus (RABV) 
glycoprotein pseudotypes of M-PMV were unaffected by the antiviral effects of SERINC5, in 
contrast to what was observed for RABV glycoprotein pseudotyped HIV-1 and MLV cores. 
Finally, SERINC5 reduced the infectivity of PIV5 pseudotyped M-PMV cores by ~9.5-fold, just 
under our 10-fold significance cutoff. 
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DISCUSSION 
 
Initial reports indicated that the viral glycoprotein is a determinant of sensitivity to 
SERINC5 antiviral activity (17, 18, 25, 26) and suggested that viral glycoproteins which mediate 
fusion via a pH-dependent, endocytic entry pathway are resistant to SERINC5 antiviral activity 
(17, 24). Here, to examine these issues further, pseudotypes using glycoproteins from diverse 
families of enveloped viruses were assessed for sensitivity to restriction by SERINC5. We 
observed that SERINC5 restricted virions pseudotyped with glycoproteins from several 
retroviruses (HIV-1, A-MLV, RD114, and M-PMV), influenza A (Orthomyxoviridae), and 
rabies (Rhabdoviridae). To our knowledge, this is the first time antiviral activity of SERINC5 
has been described for a non-retroviral glycoprotein. As the glycoproteins of these viruses were 
studied as retroviral pseudotypes, it remains to be established if the infectivity of authentic 
influenza or rabies viruses are affected by SERINC5, or other SERINC family members. 
Additionally, our observation with influenza A and rabies glycoproteins demonstrates that 
mediating entry via an endocytic route does not, in itself, protect from the antiviral effects of 
SERINC5.  
While Env glycoproteins from the retroviruses HIV-1, MLV, and RD114 have all 
previously been found to be inhibited by SERINC5 (17, 18), we now report that M-PMV 
glycoprotein is SERINC5-sensitive as well. Interestingly, we saw a ~100-fold reduction in 
infectivity of autologously pseudotyped M-PMV cores when produced in the presence of 
SERINC5. This observation was unexpected given that lenti- and gammaretroviruses encode 
accessory factors that counteract SERINC5 activity. And yet, functionally intact M-PMV (the 
only viral gene known to be missing from the GFP-expressing M-PMV vector is Env, which is 
complemented in trans during the transfection) was sensitive to the antiviral effects of human 
SERINC5. 
Surprisingly, we observed that particular glycoproteins displayed different sensitivity to 
the antiviral effects of SERINC5 depending on the viral core onto which they were pseudotyped. 
For instance, rabies virus glycoprotein was inhibited by SERINC5 when on HIV-1 or MLV 
cores, but insensitive to SERINC5 when on M-PMV cores. In contrast, M-PMV glycoprotein 
was sensitive to SERINC5 restriction when on MLV or M-PMV cores, but resistant when on 
HIV-1 cores. Additionally, a ~17-fold SERINC5-mediated inhibition was observed for M-PMV 
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cores pseudotyped with RD114 Env, while 7.5-fold and 4.3-fold inhibitions were observed for 
RD114 pseudotypes of MLV and HIV cores, respectively. A previous report demonstrated 
similar magnitude inhibition for RD114-pseudotyped MLV by endogenous SERINC activity 
(24). Regardless, RD114 showed little sensitivity to SERINC5 when pseudotyped onto HIV-1 
cores. Neutralization by monoclonal antibodies that target the membrane-proximal domain of 
HIV-1 glycoprotein is altered by the presence of SERINC5 (19, 25). Given that MA, the 
membrane proximal domain of gag makes contacts with the retroviral TM (40, 41), one can 
imagine that SERINC5 has the potential to influence interactions between MA and TM in the 
HIV-1 virion that are essential for infectivity. In similar fashion, SERINC5 might influence 
retroviral core interactions by the heterologous glycoproteins tested here, for which SERINC5 
restriction activity was core-dependent, i.e., the rabies virus, MPMV, and RD114 glycoproteins. 
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MATERIALS AND METHODS 
 
Plasmid DNA. Plasmids used in this study are described in Table 1, including Addgene or NIH 
AIDS Reagent Program code numbers (where applicable), where full plasmid sequences can be 
obtained. A pcDNA3.1 based vector bearing codon-optimized pNL4-3 env with a cytoplasmic 
tail truncation after residue 710 (HXB2 residue 712), similar to that previously described (42), 
was generated using standard cloning techniques and is available from Addgene. 
 
Cell culture. HEK293 cells were obtained from the ATCC. The HIV indicator cell line TZM-bl 
(Cat#8129) was obtained from the AIDS Research and Reference Reagent Program (Division of 
AIDS, NIAID, NIH) and were deposited by Drs. John C. Kappes and Xiaoyun Wu (43). Both 
cell lines were maintained in DMEM supplemented with 10% FBS and 10 mM HEPES. 
 
Virus production, and transductions. All viral stocks were generated by Mirus TransIT-LT1 
(Mirus Bio, Madison, WI) mediated transfection of HEK293 cells. 12 well plates were seeded 
with 3x105 cells per well 24 hours prior to transfection. In the evening of the following day, 
3.375 μl LT1 reagent was used to transfect plasmids as follows: For the production of 
pseudotyped HIV-1 virions 625 ng pNL-EGFP/CMV/WPRE∆U3 (44) and 465 ng 
pCD/NL‑BH*∆∆∆ (45) were co-transfected with 155 ng glycoprotein expression vector. For the 
production of pseudotyped MLV virions 625 ng pLXIN-GFP (46) and 465 ng pCS2+mGP (47) 
were co-transfected with 155 ng glycoprotein expression vector. For the production of 
pseudotyped M-PMV virions, 1090 ng pSARM-EGFP (48) was co-transfected with 155 ng 
glycoprotein expression vector. In all cases, either 100ng pcDNA-SERINC5 (17) or 110 ng 
empty pcDNA3.1 (Thermo Fisher Scientific, Waltham, MA) vector was included in these 
transfections. The morning following transfection medium was replaced with fresh DMEM and 
virus containing supernatant was harvested 48 hours after media change. This supernatant was 
spun for 10 minutes at 2,500 x g to remove cellular debris and stored at 4°C until used for 
transduction. 
HEK293 or TZMbl cells were seeded at 1x105 or 5x105, respectively, in 12-well plates 24 
hours prior to transduction. For experiments involving ecotropic MLV or avian leukosis virus A, 
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HEK293 cells were transfected in 6-well plates with 2.5 μg of pBABE-puro-mCAT or pCMMP-
TVA800 using TransIT-LT1  and the subsequent day these transfected cells were split and plated 
for transductions. For transductions, culture supernatant was replaced with three dilutions of 
virus containing supernatant and incubated overnight at 37°C. Virus containing medium was 
replaced and cells were incubated for an additional 48 hours, following which they were 
trypsinized and assessed for GFP expression via fluorescent activated cell sorting using the 
Accuri C6 (BD Biosciences, San Jose, CA). Analysis was performed using FlowJo Macintosh 
v10.1 (FlowJo, LLC, Ashland, OR).  
 
Virion purification and western blotting. Viral pseudotypes were produced as above, except 
transfections were performed in 6-well plates so the number of cells plated and DNA introduced 
were doubled. The resulting virus-containing supernatant was overlayed on 20% sucrose in TNE 
buffer (50 mM TRIS, 100 mM NaCl, 0.1 mM EDTA, pH7.4) and viruses were pelleted via 
ultracentrifugation for 2 hours at 125,000 x g at 4°C using an SW55-Ti rotor (Beckman Coulter, 
Indianapolis, IN). Following centrifugation, tubes were washed with 1 ml of ice cold PBS and 
viral pellets were directly lysed in 50 μl 2x Laemmli buffer containing 50 mM TCEP [Tris(2-
carboxyethyl)phosphine] incubated at room temp for 5 minutes. Cell lysates were prepared in 
parallel by washing transfected HEK293s once with 1 ml ice cold PBS, detaching from the plate 
by scraping, pelleting, and subsequently lysing for 20 minutes on ice in 150 μl SERINC lysis 
buffer (10 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM TCEP [Tris(2-carboxyethyl)phosphine], 
1% DDM [n-Dodecyl-β-D-maltoside]) containing cOmplete mini protease inhibitor (Sigma-
Aldrich, St. Louis, MO). Lysates were clarified by centrifugation for 5 minutes at 10,000 x g and 
4°C, following which supernatants were transferred to a new centrifuge tube and protein content 
was quantified via Reducing Agent Compatible BCA Assay (Thermo Scientific, Waltham, MA) 
Volumes of lysate corresponding to equal protein content were combined 1:1 with 2x Laemmli 
buffer containing 50 mM TCEP and incubated at room temp for 5 minutes.  
One half of the denatured viral pellet and approximately 8 μg protein from cellular lysates 
were run on 4-15% gradient acrylamide gels, and transferred to nitrocellulose membranes. 
SERINC5 levels were assessed via C-terminal HA tag using the mouse monoclonal HA.11 
(Biolegend, San Diego, CA) at 1 μg/ml in Odyssey blocking buffer (LI-COR Biotechnology, 
Lincoln, NE). HIV-1 p24 was detected using human monoclonal antibody 241-D (49) at a 
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concentration of 1 μg/ml in Odyssey blocking buffer. MLV p30 was detected with rat 
monoclonal antibody R187 (50) from unpurified culture medium following five days of culturing 
the R187 hybridoma (ATCC, Manassas, VA). This medium was diluted 1:200 in Odyssey 
blocking buffer. Cellular actin was detected using mouse anti-actin monoclonal ACTN05 (C4) 
(Abcam, Cambridge, MA) at a concentration of 0.5 μg/ml in Odyssey blocking buffer. All blots 
were developed using 1:10,000 dilutions of 680RD or 800CW fluorescently tagged secondary 
antibodies (LI-COR Biotechnology, Lincoln, NE) in Odyssey blocking buffer. Imaging of blots 
was performed using an Odyssey CLx system (LI-Cor Biotechnology) at a resolution of 84 μm 
using the ‘high quality’ setting. Quantitation of bands was done using the box tool in the 
Odyssey software package with adjacent pixels to the box serving as reference background levels 
for background subtraction.  
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FIGURE LEGENDS 
 
Figure 1. Sensitivity of HIV-1 pseudotypes to SERINC5 antiviral activity. (A) Effect of 
SERINC5 on transduction efficiency by HIV-1 cores pseudotyped with a diverse panel of viral 
glycoproteins. With the exception of HIV-1 pseudotypes, transductions were conducted in 
HEK293 cells. For transductions involving ecotropic MLV or avian leukosis virus A 
pseudotypes, target HEK293 cells were transfected with viral receptor prior to transductions. 
TZMbl cells were used to evaluate infectivity of HIV-1 pseudotypes. (B) Sensitivity of filoviral 
glycoprotein pseudoviruses to SERINC5. Plotted is the difference in infectivity between virus 
produced in the absence versus the presence of SERINC5. Each condition shows results of 
vector production from at least three independent transfections. The red lines indicates 10-fold 
lower infectivity in the presence of SERINC5, our arbitrary cut off for SERINC sensitivity. HIV-
1: human immunodeficiency virus-1, ALV-A: avian leukosis virus A, HERV-K: human 
endogenous retrovirus K, RD114: feline endogenous retrovirus RD114, M-PMV: Mason-Pfizer 
monkey virus, EcoMLV: ecotropic MLV, AMLV: amphotropic MLV, HTLV-1: human T-cell 
lymphotropic virus-1, Flu: influenza type A, PIV5: parainfluenza virus 5, RABV: rabies virus, 
LCMV: Lymphocytic choriomeningitis virus, MARV: Marburg virus, EBOV: Mayinga isolate 
of Zaire ebolavirus, SARS CoV: severe acute respiratory syndrome coronavirus, VSV: vesicular 
stomatitis virus, LLOV: Lloviu virus, RESTV: Reston virus, SUDV: Sudan virus, BDBV: 
Bundibugyo virus, TAFV: Taï Forest virus, Mayinga: Mayinga isolate of Ebola virus, Makona: 
Makona isolate of Ebola virus. 
 
 
Figure 2. Incorporation of SERINC5 into HIV-1 pseudovirus does not correlate with sensitivity 
to its antiviral effects. (Top) Western blots of purified HIV-1 pseudovirions produced in the 
presence or absence of C-terminally HA-tagged SERINC5. Blots were probed with mouse 
monoclonal anti-HA and human anti-p24 monoclonal 241-D. (Bottom) Western blots of lysates 
from producer HEK293s of the pseudovirions shown above. Blots were probed with mouse anti-
actin in addition to anti-HA and anti-p24 used for purified pseudovirions. 
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Figure 3. Differential sensitivity of glycoproteins to SERINC5 antiviral activity based on the 
vial core onto which they are pseudotyped. Effects of SERINC5 on the HEK293 infectivity of a 
diverse panel of viral glycoproteins pseudotyped on (A) MLV or (B) M-PMV cores. Infectivity 
was assessed as described in Fig. 1. Plotted is the difference in infectivity between virus 
produced in the absence versus the presence of SERINC5 from at least three independent 
transfections. The red line indicates 10-fold lower infectivity in the presence of SERINC5, our 
arbitrary cut off for SERINC sensitivity. 
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Table 1. Magnitude restriction of the indicated pseudotypes by SERINC5  
 
 HIV Core MLV Core M-PMV Core 
  
Fold 
Restriction 
SEM n Fold 
Restriction 
SEM n Fold 
Restriction 
SEM n 
HIV-1 132.9 35.6 3 23.5 10.5 3 360.1 181.1 3 
ALV-A 3.6 1.0 4 3.4 0.6 4 3.9 1.2 4 
HERV-
K 
1.2 0.3 3 3.2 1.4 5 1.2 0.2 4 
RD114 4.6 0.7 4 7.4 2.5 5 24.8 10.9 6 
M-PMV 1.5 0.2 3 46.3 18.6 6 104.2 31.8 8 
EcoML
V 
1.7 0.6 3 2.3 0.6 4 3.2 1.6 5 
A-MLV 123.8 22.7 12 61.7 33.7 7 315.8 87.9 12 
HTLV-1 1.2 0.4 3 2.1 0.8 5 1.1 0.2 4 
Flu (H7) 27.3 10.6 5 67.1 27.2 4 31.2 9.6 8 
PIV5 2.1 0.7 6 2.8 0.9 3 9.6 3.5 7 
Measles 2.0 0.2 4 1.5 1 3 1 0.1 4 
RABV 12.0 3.6 3 24.2 10.9 6 1.2 0.5 4 
LCMV 4.1 1.1 3 1.2 0.1 3 5.1 2.4 7 
MARV 1.9 0.5 3 2.6 0.4 3 3.2 0.8 4 
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EBOV 1.9 0.1 3 4.6 1.7 3 1.7 0.2 4 
SARS- 
CoV 
0.9 0.2 5 3.5 1.0 4 1 0.2 4 
VSV 3.1 0.6 11 1.1 0.2 6 1.0 0.1 11 
 
 
 
 
 
Table 2. List of expression plasmids used in this study 
Glycoprotein Plasmid Source Addgen
e # 
Reference 
ALV EnvA pCB6-EnvA Judith White (Univ. of 
Virginia) 
74420 (51) 
LCMV 
Arm53b 
pCMV WT GP Juan de la Torre (Scripps 
Research) 
N/A (52) 
C-term. 
truncated 
SARS CoV S 
pKS-SARS-
SΔ19 
Shuetsh Fukushi (National 
Institute of Infectious 
Diseases, Japan) 
N/A (53) 
M-PMV Env pTMT Eric Hunter (Emory Univ.) N/A (54) 
HTLV-1 Env pV1/HTLV Paul Bieniasz (Rockefeller 
Univ.) 
N/A (55) 
MLV Eco 
Env 
pHCMV-
EcoEnv 
Miguel Sena-Esteves (Univ. 
of Mass. Med. School) 
15802 (56) 
MLV Ampho 
Env 
pHCMV-
AmphoEnv 
Miguel Sena-Esteves (Univ. 
of Mass. Med. School) 
15799 (56) 
HERV-K Env pCAGGS-
HERV-K 
Sean Whelan (Harvard 
Univ.) 
N/A (57) 
PIV5 F pCAGGS-PIV5 
F 
Sean Whelan (Harvard 
Univ.) 
N/A (58) 
PIV5 HN pCAGGS-PIV5 
HN 
Sean Whelan (Harvard 
Univ.) 
N/A (58) 
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Flu HA 
(H7/Kp 
Rostock) 
pFPV-HA John Olsen (Univ. of North 
Carolina Chapel Hill 
[Emeritus]) 
N/A (59) 
Flu NA 
(H1N1; 
A/PR/8/34) 
pEF6-NA John Olsen (Univ. of North 
Carolina Chapel Hill 
[Emeritus]) 
N/A (60) 
Flu M2 pCB6-M2 John Olsen (Univ. of North 
Carolina Chapel Hill 
[Emeritus]) 
N/A (61) 
C-term. 
truncated 
Measles F 
pCG-FΔ30 Els Verhoyen (Ecole 
Normale Supérieure de 
Lyon) 
N/A (62) 
C-term. 
truncated 
Measles H 
pCG-HΔ24 Els Verhoyen (Ecole 
Normale Supérieure de 
Lyon) 
N/A (62) 
RD114A Env 
with Ampho 
MLV Env 
cytoplasmic 
tail 
phCMV-
RD114/TR 
François-Loïc Cosset (Ecole 
Normale Supérieure de 
Lyon) 
N/A (63) 
VSV G pMD2.G Didier Trono (Ecole 
Polytechnique Federale de 
Lausanne) 
12259  
Rabies virus 
G 
pLTR-RVG Jakob Reiser (US FDA) 17577 (64) 
Mayinga 
EBOV GP 
pCB6-Zaire 
EBOV 
Graham Simmons (Univ. of 
California, San Francisco) 
N/A (65) 
Sudan Ebola 
GP 
pCB6-Sudan 
EBOV 
Graham Simmons (Univ. of 
California, San Francisco) 
N/A (65) 
Reston Ebola 
GP 
pCB6-Reston 
EBOV 
Graham Simmons (Univ. of 
California, San Francisco) 
N/A (65) 
Ravn MARV 
GP 
pCAGGS-
MARV 
Graham Simmons (Univ. of 
California, San Francisco) 
N/A (66) 
Bundibugyo 
Ebola GP 
pCAGGS-
BDBV 
Graham Simmons (Univ. of 
California, San Francisco) 
N/A (67) 
.CC-BY-NC-ND 4.0 International licensenot certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (which wasthis version posted September 24, 2019. . https://doi.org/10.1101/780577doi: bioRxiv preprint 
 25
Taï Forest 
Ebola GP 
pcDNA6-TAFV Graham Simmons (Univ. of 
California, San Francisco) 
N/A (67) 
Lloviu Ebola 
GP 
pCAGGS-
LLOV 
Graham Simmons (Univ. of 
California, San Francisco) 
N/A (67) 
Makona 
EBOV GP 
pGL4.23 WT 
2014 EBOV 
ΔMuc 
N/A 86021 (36) 
A82V 
Makona 
EBOV GP 
pGL4.23 A82V 
2014 EBOV 
ΔMuc 
N/A 86022 (36) 
C-term. 
truncated 
NL4.3 Env 
(C/O) 
pcDNA-NL4.3 
Env ΔCT 
N/A Pending This Work 
GPI anchored 
TVA 
pCMMP-
TVA800 
Edward Callaway (Salk 
Institute) 
15778 (68) 
murine CAT1 pBABE-puro-
mCAT1 
Massimo Pizzato (Univ. of 
Trento) 
N/A (23) 
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Diehl et al, Figure 1
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Diehl et al, Figure 2
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